We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 11, 2021

Efficacy and Safety of Zimberelimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

European Journal of Cancer


Additional Info

European Journal of Cancer
Efficacy and Safety of GLS-010 (Zimberelimab) in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Phase II Study
Eur. J. Cancer 2021 Aug 27;[EPub Ahead of Print], N Lin, M Zhang, H Bai, H Liu, J Cui, X Ke, H Zhang, L Liu, D Yan, Y Jiang, A Zang, J Qi, L Wang, Z Liu, B Xu, Y Zhang, Z Zhang, X Zhao, C Hu, S Yang, H Zhou, J Shi, Z Shao, Y Xiang, J Zhu, Y Song, J Zhu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading